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CHAPTER I 
 
INTRODUCTION AND STATEMENT OF THE PROBLEM 
 
The drug policy in the United States is in shambles. No matter what one’s 
political leanings, it is clear that the country is in dire need of drug policy reform. 
Initiatives such as Proposition 19, which attempted to legalize marijuana in California in 
2010, have gained national attention, and much of the media’s focus on drug reform 
revolves around efforts to medicalize, decriminalize, or legalize marijuana. However, 
many of the laws and policies that regulate other drugs have even more devastating 
consequences, both for those who use them and for the rest of society. 
According to a survey by the National Institute on Drug Abuse (NIDA), almost 
four million Americans have used heroin in their lifetimes, and as of 2003 over 300,000 
had used heroin in the past year.1  Heroin, which is one of the most addictive recreational 
drugs, kills approximately 2,000 people every year.2  Addiction psychiatrist Dr. Matthew 
Tessena notes that heroin has a capture rate—the percentage of first-time users that 
eventually become dependent on the drug—of 29 percent, higher than any other drug.3  
Randy Brown provides an even higher estimate in the Wisconsin Medical Journal, 
claiming that as many as 53 percent of people who try heroin eventually become 
dependent on it. In 2002, the Drug Abuse Warning Network (DAWN) reported 93,519 
emergency room visits involving heroin.4 
The graph below is a ranking of the harm of twenty commonly abused drugs, both 
legal and illegal. Two independent groups of experts rated each drug on a four-point scale 
in the categories of social harm, physical harm, and dependence. The scores were 
averaged with equal weight for each category, yielding the following results. 
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As you can observe, heroin was rated as the most harmful of all twenty drugs studied by a 
significant margin. 
Heroin addicts experience intense negative withdrawal symptoms such as nausea 
and vomiting that exacerbate the difficulties associated with overcoming the addiction 
and make it nearly impossible to quit without professional medical help. Mash et al. 
explain, “The acute withdrawal syndrome in addicts dependent on heroin begins 
approximately 8 hours after the last heroin dose, peaks in intensity at 1 to 2 days, and 
subjective symptoms subside within 7 to 10 days.”6  The most recent volume of the 
Diagnostic and Statistical Manual of Mental Disorders—the standard endorsed and 
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published by the American Psychiatric Association for the classification of mental 
disorders—now recognizes substance abuse as a mental disorder.7  And yet, we continue 
to imprison thousands of people for suffering from this disease. 
As of June 2009, there were almost 2.3 million people incarcerated in American 
prisons, and an astonishing 60 percent of federal prisoners were incarcerated for drug-
related offenses.89  Not only does this mass imprisonment cost American taxpayers 
millions of dollars, it has also led to severe overcrowding in prisons across the country. In 
2009, a federal court ordered California to reduce the prison population because 
“California’s prisons remain severely overcrowded, and inmates in the California prison 
system continue to languish without constitutionally adequate medical and mental health 
care.”10  Reducing the number of people sent to prison for personal drug use would thus 
also benefit the millions of inmates suffering the effects of cramped prisons.  
A report by the Substance Abuse and Mental Health Services Administration 
(SAMHSA) estimated that illicit drug addiction cost the United States economy $160 
billion in 2000, and that this number would continue to rise.11  These expenses are the 
aggregate of spending on medical care, lost productivity, crime, and incarceration. 
Imprisoning a single person for one year has an estimated cost of approximately $30,000, 
and that does not include the costs of arrest and prosecution.12  As the United States 
attempts to recover from one of the worst recessions in recent memory, we cannot afford 
to incur such high costs in the name of maintaining the status quo. It is important to note, 
though, that many of these “costs of addiction” may in fact be unintended consequences 
of the laws that regulate these drugs. In Drugs and Society: U.S. Public Policy, Jefferson 
Fish argues, “Opponents of drug prohibition have long recognized that the great majority 
  7 
of social ills attributed to drugs are actually the result of the War on Drugs—and 
specifically of the colossal black market created by prohibitionist policy.”13 
Heroin addicts are at special risk for contracting certain diseases because the 
primary method of heroin use is by a needle injection. This has led many European 
countries, and some American cities, to enact needle exchange programs. However, 
opponents of these programs argue that they encourage the use of illegal drugs and 
function as an implicit government endorsement of illicit drug use. 
Currently, the primary method of treatment for heroin addiction is a drug called 
methadone. But methadone itself is a dangerous and addictive drug, and surely an 
insufficient solution to the problem of heroin addiction. Detoxification is another 
common option. “Detox” consists of staying at a drug-free facility and waiting until the 
symptoms of withdrawal eventually subside. However, NIDA reports, “Not in itself a 
treatment for addiction, detoxification is a useful step only when it leads into long-term 
treatment that is either drug-free (residential or outpatient) or uses medications as part of 
the treatment.”14 
Another treatment option for people battling heroin addiction is ibogaine, but 
there’s a catch: ibogaine is an illegal Schedule I drug (on par with heroin itself) in the 
United States. Ibogaine comes from the root of the west African plant Tabernanthe 
Iboga. In 1962, a heroin addict named Howard Lotsof bought some of the iboga plant in a 
quest to find a new and exciting trip. Instead, after an introspective journey that lasted 
more than a day, Lotsof discovered that when the effects of the plant subsided, he no 
longer felt the usual craving for a heroin fix. Lotsof gave the drug to seven fellow drug 
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addicts, and five out of seven immediately quit their addictions.15  In 1985, Lotsof was 
finally awarded a patent for ibogaine for the use of opioid withdrawal.16 
Between 1962 and 1995, numerous scientists, researchers, and activists attempted 
to study and patent ibogaine and its metabolites. However, ibogaine was classified as a 
Schedule I drug in 1967, and the National Institutes of Health (NIH) discontinued 
funding for research on ibogaine in 1995. Schedule I drugs are defined as having no 
legitimate medical purpose and a high potential for abuse. 
All of the major societal problems associated with heroin use demonstrate that the 
United States is losing its so-called War on Drugs. The judicial system spends precious 
time and money to crowd the prisons with non-violent people, the streets are home to too 
many junkies, countless families are destroyed, hospitals are filled with users whose 
addictions nearly kill them, and thousands of less fortunate users die every year. And yet, 
there have been no attempts at sweeping drug policy reform by Congress. There have 
been small victories such as medical marijuana legislation, marijuana decriminalization, 
and laws fixing sentencing disparities between crack and cocaine, but these are all minor 
tweaks, not solutions to the systemic failures of American drug policy. The following 
chapters will explore specific ideas for reform that can effectively combat the problems 
that result from rampant drug abuse and the harmful policy of prohibition.  
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CHAPTER II 
THE HISTORY OF HEROIN USE IN THE UNITED STATES 
 
 
 In the 1800s, before heroin was known in the United States, there was an 
epidemic of addiction to morphine and opium. The number of opiate addicts rose from no 
more than 0.72 addicts per thousand Americans prior to 1842 to a whopping 4.59 addicts 
per thousand in the 1890s.17  Heroin was introduced as a cough suppressant in 1898, and 
it quickly led to mass addictions in the New York City area. Unlike morphine and opium 
use, heroin use was strongly concentrated in urban areas. In fact, David T. Courtwright 
reports in Dark Paradise: A History of Opiate Addiction in America, “by 1920, probably 
9 out of 10 American heroin addicts were within 180 miles of Manhattan.”18 
 Initially, heroin was thought to have no addictive potential, and it was even 
prescribed fairly commonly as a cure for morphine addiction. But by the 1910s, with 
heroin addictions on the rise, physicians finally took notice and began to decrease heroin 
prescriptions. In 1919, the American Medical Association called for a total ban on 
heroin.19 
 One of the contributing factors to the rise of heroin addiction was the Smoking 
Opium Exclusion Act of 1909. While opium was still available subsequent to these 
regulations, it became far more expensive and could only be acquired in minimal 
quantities. Heroin, on the other hand, was cheap and accessible. The early 1900s also saw 
severe restrictions on the legality of cocaine, in turn raising the price of cocaine, and 
leading many former cocaine users to switch to heroin. 
 In 1914, Congress passed the Harrison Narcotics Tax Act, which heavily 
regulated opiates while still allowing for their prescription by licensed medical 
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practitioners. Many physicians continued to prescribe heroin to addicts to maintain their 
addictions, but in 1919, in Webb et al. v. United States, the Supreme Court held that 
physicians could no longer prescribe heroin for the sole purpose of maintaining a 
patient’s addiction. Many maintenance clinics sprung up in response to this decision, but 
the Narcotic Division of the Prohibition Unit of the Bureau of Internal Revenue strongly 
opposed them, and succeeded in shutting almost all of them down by 1921.20 
 All of these changes in policy and law were reflected in changes in the addict 
population. Initially, morphine addicts were primarily iatrogenic addicts, meaning they 
became addicted after a doctor prescribed them morphine. The addicts of the 19th and 
early 20th centuries were also heavily white, female, and upper or middle class. Caroline 
Jean Acker writes, “[i]f her habit became known to others besides her physician, she 
typically became an object of pity.”21  As doctors stopped readily prescribing opiates, the 
addicted population evolved and became dominated by lower-class criminals in the inner 
cities. Courtwright argues, “the transformation of the addict population was a necessary 
condition for public support of the ‘police approach’ to opiate addiction.”22  After this 
transformation, the sympathy the public had previously held for addicts morphed into 
disdain. Acker echoes this sentiment, and contrasting the pity felt for the mother addicted 
to morphine, she observes that if caught, the heroin addict “faced not only legal sanctions 
but also profound stigma.”23  Understanding the composition of the addict population is 
integral to understanding the public’s reaction to heroin use. “A demographic subgroup 
reacting to a particular set of public policy and historical changes, these addicts gave rise 
to an image of deviance that has shaped American drug policy ever since and helped 
reinforce the moral underpinnings of the war on drugs.”24  This view that addicts were 
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lower-class criminals justified heroin prohibition at the same time that Americans were 
celebrating the repeal of alcohol prohibition. Unlike heroin, alcohol was abused fairly 
equally across all social classes.  
 Then came the United States’ involvement in World War II in 1941. Not only did 
the war severely restrict the supply lines of foreign heroin into the United States, it also 
sent twelve million young American men to war. In combination, these two factors 
almost eliminated heroin use in the United States from 1942 to 1945. Heroin was scarce 
and expensive, and there were almost no new young addicts in the wartime years. For 
example, Bellevue Hospital in New York City did not admit a single adolescent heroin 
addict between 1940 and 1948.25  But after the war ended, the soldiers returned from 
abroad, and the supply lines reopened. The epidemic was about to begin. in the first two 
months of 1951, Bellevue Hospital alone admitted eighty-four adolescent addicts; 
meanwhile, federal narcotics arrests soared from 2,827 in 1947 to 5,522 in 1950.26  The 
addict population also evolved further, as blacks and Hispanics began to replace whites as 
the majority of heroin addicts, and use became concentrated in ghettos and barrios. Part 
of the reason for this was that in the mid-20th century, many blacks migrated to northern 
cities with abundant supplies of heroin such as Chicago, New York, and Detroit. 
Moreover, Courtwright points out, “Whites who did succumb to addiction enjoyed 
familial support and recovery resources that many minority addicts lacked…Minority 
users had a harder time escaping their drug-filled and socially isolated neighborhoods.”27 
In reaction to this new surge of postwar addicts, Congress passed the Boggs Act 
in 1951 and the Narcotic Control Act in 1956, even though heroin use had peaked before 
the laws were actually put into effect. The Boggs Act established sentences for 
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possession of two years for a first offense, five for a second, and ten for a third. The 
Narcotic Control Act added a minimum five-year sentence for a first dealing offense, and 
a ten-to-forty-year sentence for a second offense or for sale to a minor. It even allowed 
for capital punishment, at the jury’s discretion, in the case of an adult selling to a minor.28  
Heroin use continued to decline minimally, but surged again in the 1960s. Courtwright 
calls this wave “a baby-boom phenomenon,” explaining, “42 million baby-boomers, born 
between 1946 and 1956, were entering their most heroin-susceptible years…There were 
11 million more young people in the country in 1970 than in 1960, and they were part of 
a huge, autonomous youth culture that romanticized drug use.”29  The problem was 
exacerbated when thousands of American troops returned from Vietnam and continued 
heroin habits they had picked up abroad. 
One of the responses to this epidemic was the explosion of Methadone 
Maintenance Treatment (MMT) programs. Although methadone had been developed in 
1941 and first used to treat heroin addicts in 1963, there were only a few hundred heroin 
addicts on methadone in 1967.30  In 1971, there were 9,000 patients maintained on 
methadone, and this number ballooned to 73,000 by 1973.31  This emphasis on treatment 
did not preclude a comparable increase in the efforts of police enforcement. But despite 
President Reagan’s attempts at supply reduction, heroin prices steadily dropped in the 
1980s and continued to drop in the 1990s, even as the purity of street heroin rose to 
unprecedented levels. The so-called War on Drugs became heavily politicized and linked 
with crime prevention efforts. According to Courtwright, “drug policy, no longer tied 
primarily to concerns about heroin, ceased to be tied exclusively to drugs at all, having 
evolved into a reelection, crime-prevention, revenue-transferring, culture-war 
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omnibus.”32  Clearly, the current trend is unacceptable and requires a new approach to 
public policy. 
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CHAPTER III 
 
THE CYCLE OF ADDICTION AND INCARCERATION 
 
  
Addicts encounter numerous barriers in their struggle to turn their lives around. 
One of these obstacles is the devastating and self-perpetuating cycle of addiction and 
incarceration. This is especially true for poor or homeless addicts, and heroin is widely 
abused by those in severe poverty. As Randy Brown reports, “Indicators of a low 
socioeconomic status (SES) have consistently been associated with heroin use and 
dependence…[including] measurements of individual income and occupation as well as 
neighborhood-level indicators of SES.”33 
The cycle begins like this: Imagine that your poverty-stricken life is so miserable 
that you look for a release in heroin to help escape reality. Like many users (recall 
heroin’s high capture rate), you become addicted to heroin, and spend any spare cash to 
support your habit. One day, the police arrest you and you are sent to prison. In prison, 
you are exposed to violent criminals, possibly subjected to physical abuse, and damaged 
psychologically as you are made to feel as worthless as a caged animal. You crave a fix 
more than anything, and receive inadequate medical attention for the painful withdrawal 
you experience. When you are eventually released back into society, you try to turn your 
life around. But staying clean without professional help is an insurmountable task. 
Moreover, you are thrown back into society with little guidance, just as poor as you were 
on your way into prison. You now face the daunting task of trying to secure stable 
employment—hard enough in the present economy—made even more difficult by the 
fact that you are an ex-convict, immediately disqualifying you from many job 
opportunities. You may also face stigmatization in your community or among friends and 
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family who do not wish to associate with ex-convicts. With prospects like these, who 
wouldn’t relapse?  And so, the cycle continues. You give up on your dreams of a healthy 
and normal life, and succumb to the temptation of the one thing that allows you to feel 
good again without feeling your world collapse all around you. Naturally, you are likely 
to find yourself back in prison before too long, whether because of drug charges, or 
because you are forced to commit crimes such as theft to support your addiction. 
So what are we to do about this problem?  It seems unethical to punish someone 
for their entire life because they haven’t been able to correct a mistake they made, 
perhaps as an adolescent. One problem of the current system is that it does not properly 
take into account these types of extenuating circumstances that drive individuals to break 
the law. An attempt to combat this problem is the recent explosion of drug courts. 
The first drug court was established in Florida in 1989, and there are now 
hundreds of similar courts throughout the United States.34  They combine community 
treatment, counseling, and drug-testing to try to help participants overcome their 
addictions and become contributing members of society. Gottfredson, Najaka, and 
Kearley explain, “Drug treatment courts are designed to increase the likelihood that drug-
addicted offenders will seek and persist longer in drug treatment, which is expected to 
help these individuals reduce their drug dependence and develop healthier, more 
productive, and drug-free lifestyles.”35  Drug courts are more personal than regular 
courts, and treat each person as an individual, not as a statistic, or just another generic 
heroin addict.  
In Hooked, Lonny Shavelson relates the story of Crystal Holmes, a heroin addict 
and dealer who has been in and out of prison for much of her adult life. Like many 
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inmates arrested on drug charges, Crystal was brought into drug court one day to observe 
the proceedings in the case of Brian Walker, a 20-year-old heroin addict. Crystal could 
not believe what happened next. The presiding judge, Judge Lam, said to Brian, “I am so 
sad that we’ve come to this point, that we are about to take you out of Drug Court and 
send your case back to criminal court. I had such high hopes for you, and I am hurt to my 
heart…I want you to want your future as much as I want it for you!”36  The emotion and 
personal connection shocked Crystal, who had no previous experience with the drug 
court system. It also persuaded Crystal to take the court’s offer to move her case from 
criminal court to drug court. According to Judge Jeffrey Tauber, the director of the 
National Drug Court Institute, “The Drug Court is theater.”37  That is exactly why 
inmates such as Crystal are brought in to watch the proceedings. Dr. Sally Satel, an 
expert on drug courts, notes, “Drug court is fertile ground for the unfolding of 
psychological drama…The depth of involvement with the defendant is unprecedented.”38  
But what does the research say?  Are drug courts really effective?  Is Crystal better off 
than she would have been serving her time in prison? 
The National Institute of Justice funded a report by the Urban Institute and 
Caliber Associates that examined the national recidivism rates of drug court graduates. 
The study analyzed a sample of over 2,000 drug court graduates from 1999 to 2000 
across 95 drug courts throughout the country. The results show a recidivism rate of 16.4 
percent for drug court graduates within one year of completion of the program, and this 
rate rises to 27.5 percent after two years.39  However, as the authors of this study 
acknowledge, they simply established a baseline recidivism rate for drug court graduates, 
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but analysis on the effects of drug courts was impossible because there was no control 
group for comparison. 
Gottfredsen et al. set out to design a more rigorous study that could scientifically 
demonstrate the efficacy of drug courts and minimize the confounding variables. They 
note that a meta-analysis of forty-one studies concluded that drug courts reduce crime 
and drug use, but there were questions about the reliability and methodology of these 
studies. Many of them simply compared the outcomes of drug court graduates and non-
graduates. As Gottfredsen et al. rightly point out, “Such comparisons are problematic 
because clients self-select themselves into conditions. Nongraduates are likely to differ 
from program graduates in important ways and may be at an elevated risk for 
recidivism.”40  Instead, Gottfredsen et al. took 235 arrestees eligible for entry into the 
drug court treatment program and randomly assigned them either into the program or not. 
Although some of the participants suffered from addictions to alcohol and cocaine, the 
vast majority (77.2 percent) were in the program due to heroin addiction.41   The results 
were encouraging: while 81.3 percent of control subjects were re-arrested within two 
years, only 66.2 percent of drug court participants were re-arrested in the same time span. 
Moreover, only 40.6 percent of drug court participants were re-arrested for drug-related 
offenses in the two years after treatment began, compared with 54.2 percent of the control 
population. In addition, there were no significant differences in the outcomes of the 
minor and more severe drug users. The authors also examined how important the role of 
certified drug treatment was in recidivism. They found that of the subjects who 
participated in the drug court program but did not receive drug treatment, 75 percent were 
re-arrested within two years compared with only 56.7 percent of drug court participants 
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who underwent drug treatment as well.42  This indicates that treatment plays a significant 
role in the positive impact of drug court programs on recidivism. Thus, although drug 
court participants still recidivate at high rates (it should be noted that this study was 
conducted in Baltimore, a location known to have an abnormally high rate of recidivism, 
where 85 percent of crime is supposedly addiction-driven43), they do show clear 
improvement compared with similarly situated individuals who do not go through the 
drug court program. 
One more benefit of drug courts is that a participant who successfully completes 
the program sometimes has their criminal record wiped clean. This allows someone who 
has never committed a crime against another person to have more opportunity to find 
stable employment and get his or her life back on track. 
Another suggestion to help break this vicious cycle is the idea of in-prison 
therapeutic communities (ITCs). Hiller, Knight, and Simpson conducted a study of 396 
inmates, 293 of whom participated in an ITC. The comparison group was composed of 
103 inmates who were eligible for entry into the ITC program, but were not admitted due 
to either lack of space or other factors that had no influence on individual outcomes.44  
The inmates’ addictions ranged from cocaine to alcohol to heroin, with 38 percent of the 
group addicted to opioids. It is worth noting that only 18 percent of the participants were 
addicted to opiates before their incarceration, further demonstrating the harmful and risky 
situation people are thrown into when they are imprisoned, a far cry from a healthy 
rehabilitative setting. The participants spent nine months in an ITC and three months 
following their release from prison in Transitional Therapeutic Communities (TTCs). 
However, 123 subjects dropped out of the TTC program, so the final comparison groups 
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consisted of 103 people in the control group, 123 who completed the ITC program, and 
170 who completed both the ITC program and the full TTC program. The three groups 
were analyzed with complex multivariate analysis to assess the risks for recidivism for 
the members of each group, and the authors found that both treatment groups were 
predisposed to higher risks of recidivism. Despite this, in the thirteen to twenty-three 
months after release, 42 percent of the control group was rearrested. In contrast, 36 
percent of the ITC group was rearrested, while only 30 percent of the people who 
completed both the ITC program and the TTC program were rearrested.45  The results 
suggest that ITCs lower the risk of recidivism for drug-addicted inmates, and that follow-
up TTC programs further reduce an individual’s risk of recidivism. The authors conclude, 
“[e]ffective in-prison treatment appears to require a continuum of care that takes the 
drug-involved offender from the institutional environment to the reintegrative process of 
community-based initiatives.”46  Treatment in prison, and genuine attempts to help 
reintegrate inmates back into society after their release, are vital to ending the cycle of 
addiction and incarceration. I will return to the idea of mandatory treatment for addiction 
later in the paper. 
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CHAPTER IV 
 
METHADONE 
 
 
Methadone has long been the preferred treatment method for heroin addicts. Like 
most drugs, methadone has certain risks, and between 1999 and 2005, “Methadone-
related deaths…increased more than other narcotic related deaths.”47 Despite the fact that 
methadone was involved in 4,462 deaths in 2005—up 468 percent since 199948—the 
majority of researchers and physicians endorse methadone’s safety. In the Mount Sinai 
Journal of Medicine, Joseph, Stancliff, and Langrod report, “Medical studies have shown 
that methadone maintenance is medically safe and nontoxic, can be used effectively in 
pregnancy, and does not impair intellectual, cognitive or motor functioning.”49  It should 
be noted that a recent study published in the New England Journal of Medicine in 2010 
undermines the claims about methadone’s safety during pregnancy. “131 neonates whose 
mothers were followed to the end of pregnancy according to treatment group (with 58 
exposed to buprenorphine and 73 exposed to methadone) showed that the former group 
required significantly less morphine (mean dose, 1.1 mg vs. 10.4 mg; P<0.0091), had a 
significantly shorter hospital stay (10.0 days vs. 17.5 days, P<0.0091), and had a 
significantly shorter duration of treatment for the neonatal abstinence syndrome.50”  
Nonetheless, SAMHSA also lauds methadone’s safety, stating, “[m]ethadone has been 
shown to be safe; it produces no serious or long-term side effects.”51  Even if methadone 
is safe when properly used by an addict with a doctor’s prescription, we cannot ignore 
“the reality that methadone meant for treating patients is often diverted to the streets by 
those who are given the privilege of taking home a one-to-six-day supply of the drug.”52 
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Nonetheless, methadone has certainly been demonstrated to have definite positive 
effects on heroin addicts who undergo methadone maintenance treatment (MMT). 
Following are some of the highlights of the success of MMT programs: 
• “during the first 4 months of treatment, crime decreased from 237 crime days per year 
per 100 addicted persons during an average year of their addiction to 69 crime days 
per year per 100 patients, a reduction of more than 70 percent”53 
 
• “over a 3-year period, 5 percent of patients in methadone treatment became HIV 
positive…while among a cohort of out-of-treatment addicts in the same 
neighborhood, 26 percent became HIV positive”54 
 
• “patients can work in any capacity for which they are trained, live normal lives with 
their families and, if not infected with HIV or hepatitis C, or afflicted with other 
potentially fatal illnesses, show improvements in their health status”55 
 
Indeed, methadone has helped many addicts successfully overcome their 
addictions and return to a semi-normal life. It is also relatively cost-effective. Recall the 
exorbitant social and economic costs of heroin use. Farrell et al. found that MMT 
programs are “substantially cheaper than the cost to the community of the active or 
incarcerated drug misuser. International reports find that oral methadone maintenance is 
justifiable on a cost-benefit analysis.”56  But to claim, as SAMHSA does, that methadone 
has an “absence of any serious, long-term side effects”57 is simply disingenuous. 
Methadone was first shown to be an effective treatment for heroin addiction in 1949 
at U.S. Public Health Hospital in Lexington, Kentucky.58  In 1968, Sapira, Ball, and 
Cottrell investigated the addictive properties of methadone at that same hospital after 
“Preliminary studies of its addiction liability…demonstrated experimentally that 
methadone produced drug dependence of the morphine type.”59  They concluded, 
“Although methadone is not the drug of choice among American narcotic addicts, 214 
methadone addicts have been admitted to the Lexington and Fort Worth hospitals in 
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recent years. Methadone addiction appears to be discomforting enough to prompt persons 
to seek treatment, as evidenced by the significantly higher voluntary admission rate of 
these addicts compared with the entire narcotic addict population.”60  Shockingly, there 
seems to be very little modern research on methadone addiction and dependence. 
However, this is not because methadone magically lost its addictive power—one 
anecdotal report describes the devastating effects of methadone withdrawal: 
“I’ve been on both ends of withdrawals, heroin and methadone, every patient of 
methadone will always tell you the same, as I do; I can kick heroin anytime, but 
methadone that is something else. In 15 yrs of heroin addiction, I’ve kicked 3 
times, ‘cold-turkey’. In 10 years on methadone I’ve never kicked methadone. 
Once I landed in jail, I had to do 72 hours of jail time before I got to see the judge. 
I was literally on the floor screaming my guts out. About 12 hours before I was to 
see the judge, I demanded to be taken to the hospital, I just couldn’t take it. I was 
cuffed, and looking like a ‘chair’ was glued to my back, I limped to the 
ambulance, since I couldn’t lift my leg to climb into the back, the police grabbed 
me on both sides and shoved me in like a sack of potatoes, I fell flat on my face. 
The doctor, realizing my condition and that it was severe, gave me a shot of 
methadone. The relief was immediate. I was returned to the precinct and 2 days 
later I was in the same condition! Never did I go through such hell in all my 
days.”61 
Another internet user pleads for help in an online support forum: 
“I just can't stand it any more. Cold turkey of course did not work as I 
experienced muscle cramps and restless limbs. I have tried gradually reducing the 
amount I've taken daily until I got down to down to little tiny grains a day but the 
muscle cramps that keep me up at night have never gone away. Finally about 3 
weeks ago, I completely stopped taking even those tiny grains and keep expecting 
the cramps and restlessnes to go away. My nightly routine is made up of falling 
asleep, then waking up 30 minutes later with muscle cramps, take a hot bath, try 
to go back to sleep, take another bath, fall asleep, wake up 30 minutes later, and 
on and on and on until 4:00 am when I finally fall asleep. I am only getting about 
4 hours sleep a night and am absolutely going insane. It's been 20 days of little to 
no sleep, tossing and turning in bed. How long am I going to have to suffer this 
way until the restlessnes and muscle cramps go away? Does anyone know of 
anything that will lessen the cramps?”62 
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A simple Google search will turn up myriad equally gut-wrenching stories from 
methadone addicts suffering in anguish from withdrawal. 
Moreover, while studies rave about the effectiveness of MMT, the reports are 
often misleading. According to SAMHSA, “Consumption of all illicit drugs declines to 
less than 40 percent of pretreatment levels during the first year and eventually reaches 15 
percent of pre-treatment levels for patients who remain in treatment 2 years or more.”63  
However, this is an obviously self-selected sample, and it is evident that longer stays in 
treatment correlate with higher success rates. In the Psychology of Addictive Behaviors, 
Simpson, Joe, and Brown report, “Length of time spent in treatment has been one of the 
most reliable predictors of posttreatment outcomes in national evaluations in the United 
States.”64  To properly understand the statistic SAMHSA quotes, we must know the 
retention rate of the MMT program. As NIDA reports, an Italian study of over 1,500 
heroin addicts found that only 40 percent of addicts remained in the program after one 
year. A UK study of 351 patients had a retention rate of 62 percent after one year, but 
dropped to only 30 percent after two years.65  Neither of these studies is anomalous. 
Furthermore, follow-up studies that examined the outcomes of MMT patients found that 
once they left treatment, relapse rates were as high as 70 percent.66 These data 
contextualize SAMHSA’s claim and show just how misleading the supposed success 
rates are. If 1,000 addicts entered the MMT program with these success rates, then only 
300 or so would be left after two years. Of those, as many as 200 are likely to relapse, 
leaving only 10 percent of those who initially entered the program currently substance-
free. 
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MMT simply substitutes another drug—albeit less dangerous—for heroin. 
According to Joseph et al., “Methadone maintenance is a corrective, not a curative 
treatment for heroin addiction. It may be necessary for patients to remain in treatment for 
indefinite periods of time, possibly for the duration of their lives.”67  This is certainly far 
from ideal. Consider the psychological impact on one’s self-image when every day, a 
little pill reminds you of your powerlessness over heroin addiction. Much like Prozac can 
function as a daily reminder of a patient’s depression, methadone constantly reinforces 
the idea that heroin exercises control over an addict. Friedman and Alicea note, “Many 
self-help groups also view the use of methadone as contradictory to the goals of full 
rehabilitation and sobriety. These groups see methadone as simply the replacement of one 
addiction for another.”68 
All of this is not to say that MMT has not helped countless addicts since its 
invention as a treatment for addiction. Certainly, helping even 10 percent of addicts beat 
addiction is a great start. But it’s not enough. And there very well may be a better 
alternative—if it weren’t illegal in the United States. 
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CHAPTER V 
 
IBOGAINE: THE MIRACLE CURE? 
 
  
Ibogaine treatment is one potential alternative to MMT. Despite being illegal in 
the United States, ibogaine has many advantages over MMT. However, because of 
ibogaine’s Schedule I status, no addicts in the United States are currently receiving legal 
treatments of ibogaine. Recall that Schedule I status means that according to the United 
States Congress, ibogaine has no legitimate medical purpose and has a high potential for 
abuse. This classification alone should set off warning bells that something surreptitious 
is going on here. Even if the results of the research conducted before the NIH pulled 
funding in 1995 did not persuade Congress of ibogaine’s miraculous healing power, a 
Schedule I classification is impossible to justify. Ibogaine users experience intense 24 to 
36 hour hallucinogenic trips that often include vomiting and nausea. Much like peyote, 
which is used legally by some Native Americans for spiritual rituals, and also makes 
users violently ill, there is essentially no potential for abuse. Ibogaine has never been 
reported in any emergency room visits, police incidents, or fatalities, from recreational 
use. If ibogaine fits the profile for a drug with a high potential for abuse, so should every 
other drug. Cocaine, one of the most addictive and deadly recreational drugs, is somehow 
only Schedule II.  
Kenneth Alper, a leading researcher on ibogaine in the treatment of opioid 
withdrawal, observes, “The available evidence does not appear to suggest that ibogaine 
has significant potential for abuse… Ibogaine is reportedly neither rewarding [n]or 
aversive in the conditioned place preference paradigm. Rats given either 10 or 40 mg/kg 
ibogaine daily for 6 consecutive days did not show withdrawal signs. Animals do not 
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self-administer 18-MC, an ibogaine analog, in paradigms in which they self-administer 
drugs of abuse. None of the consultants to NIDA in the 1995 Ibogaine Review Meeting 
identified the possible abuse of ibogaine as a potential safety concern.”69  Moreover, even 
if ibogaine had a high potential for abuse, which is a claim beyond reason and 
unsupported by any evidence, it is suspect to say that it has no legitimate medical 
purpose. Ibogaine is the only drug ever discovered that may be a cure, not a treatment, for 
addiction. Even if it were dangerous and highly addictive, there is simply no justification 
or logic behind the claim that ibogaine has no legitimate medical purpose when it can 
achieve what no manmade drug has ever come close to accomplishing. Nevertheless, 
inertia is a powerful force, and ibogaine has remained a Schedule I substance since its 
initial classification as such in 1967. 
This curious classification elicits some interest in the motives behind ibogaine’s 
Schedule I status. A treatment drug is always more profitable for drug companies than a 
cure—addicts undergoing MMT have to take methadone every day, whereas part of the 
magic of ibogaine is that, at least potentially, it is a one-time cure. Drug companies also 
tend to be far more concerned with drugs that have a high profit potential, not drugs that 
primarily treat poor people. “The Pharmaceutical Research and Manufacturers of 
America (PhRMA) reports that in 1999, for example, its roster of drug giants had 10 
antiaddiction agents in clinical trials. The same companies had more than 400 cancer 
drugs in clinical development.”70  Alper points out that 90 percent of anti-addiction drug 
development in the public sector is funded by NIDA, whose annual budget is a mere $60 
million. In contrast, the average cost of developing a drug and successfully bringing it 
into the market is $300 million. Thus, Alper says, “The strategy of relying on the 
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pharmaceutical industry to underwrite the cost of drug development works extremely 
well in many instances, but appears to present some limitations with regard to the 
development of pharmacotherapy for addiction in general, and specifically ibogaine.”71  
There is even less incentive for drug companies to investigate ibogaine because since it is 
a naturally occurring alkaloid, the actual structure cannot be patented. 
Moreover, just as the criminalization of recreational drugs creates black markets 
for those drugs, there is a now a black market of underground ibogaine clinics in the 
United States. According to an article in the Journal of the American Medical 
Association, “A sophisticated ‘underground railroad’ of sorts has sprung up in New York, 
spearheaded by Dana Beal, a long-time marijuana legalization advocate.”72  One of the 
primary researchers on the effects of ibogaine, Deborah Mash, also notes this 
phenomenon, cautioning that “We’ve got this explosion of underground clinics, and I’m 
scared that everything I work for is going to go right down the toilet.”73   Even the most 
passionate ibogaine advocates do not claim that it is risk-free, and so these underground 
clinics may actually be quite dangerous, exacerbating, rather than ameliorating, the 
problem. 
So is ibogaine the miracle cure it’s cracked up to be?  The research speaks for 
itself. The chart below lists some of the benefits of ibogaine in a comparison with 
methadone and some other similar but newer drugs starting to be used to treat heroin 
addicts. 
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Before being tested on humans, ibogaine was demonstrated to reduce the self-
administration of morphine and cocaine in rats, monkeys, and mice.75  The few studies 
involving human subjects have small sample sizes, but all nonetheless indicate the 
amazing potential of ibogaine. Howard Lotsof, the father of ibogaine treatment in the 
United States, and his colleagues published a review in the American Journal on 
Addictions of thirty-three heroin-addicted patients who they had observed after 
undergoing ibogaine treatment. Specifically, they examined ibogaine’s effects on the 
well-known symptoms of heroin withdrawal. The researchers measured both subjective 
complaints of withdrawal symptoms (e.g. nausea, chills) and objective physical 
symptoms of withdrawal (e.g. vomiting, sweating). An astounding 88 percent of patients 
were free of withdrawal symptoms twenty-four hours after treatment.76  Seventy-six 
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percent of patients did not seek drugs during the seventy-two-hour period following 
treatment. Twelve percent of patients were free of withdrawal symptoms but chose to 
resume their drug use nonetheless. This result is significant because the unpleasant 
withdrawal symptoms are believed to be a major reason that heroin addicts find quitting 
so challenging. Only a single patient exhibited subjective and objective withdrawal 
symptoms, and this was believed to be due to an inadequate dose of ibogaine given her 
history of heroin use. 
There is one significant caveat to this report: one patient suffered a respiratory 
arrest 19 hours after treatment and eventually died. According to the authors, “This 
incident was a significant factor in the decision not to pursue a clinical trial of ibogaine 
following the NIDA Review Meeting held in March of 1995.”77  However, there is no 
proof that the subject actually died as a result of ibogaine use. In fact, the researchers 
found evidence in her personal effects that suggested that she might have snuck off and 
smoked heroin after treatment. Inexplicably, an autopsy, which could have confirmed 
this, was not performed. Naturally, it is understandable to be skeptical of a cure that may 
itself be lethal, but other research has further demonstrated the safety and efficacy of 
ibogaine. 
Mash et al. conducted a more extensive and controlled study of thirty-two patients 
addicted to heroin or methadone. The results were equally encouraging. Patients showed 
almost no objective signs of withdrawal over the two-week period after treatment, and 
when symptoms did occur, they were relatively minor. The results were obtained through 
three different blind and independent assessment measures, and the ratings of withdrawal 
symptoms were consistent across all three analyses. The authors conclude, “The results 
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suggest that ibogaine provided a safe and effective treatment for withdrawal from heroin 
and methadone.”78 
Mash et al. studied another group of twenty-seven patients addicted to cocaine or 
heroin with similarly positive results. They hypothesized that many addicts may self-
administer numbing drugs to help cope with depression, and so they measured depressive 
symptoms on the Beck Depressive Inventory scale, a standard objective measure of 
depression. Indeed, Brienza et al. report, “Multiple studies of opiate abuse treatment 
samples have revealed high prevalence rates of both lifetime and current major 
depressive disorder…far exceeding general population estimates.”79  Mash et al. observed 
the subjects for two weeks, and they also conducted follow-up evaluations one month 
after treatment. They found that “[a]fter treatment with ibogaine, opiate-dependent 
subjects were less likely to anticipate positive outcomes from heroin (or other opiate) use, 
less likely to believe that heroin (or opiate) use would relieve withdrawal/dysphoria, and 
more likely to believe in their control for abstaining or stopping their drug use. Ibogaine 
treatment also decreased participants’ desire and intention to use heroin.”80  Moreover, 
patients reported significantly lower levels of depressive symptoms at the one-month 
follow-up. Thus, depression is another illness that may potentially be combated with the 
help of ibogaine. 
The main concern with ibogaine treatment is the previously mentioned fatality 
and a few other deaths possibly related to ibogaine reported in the literature. Alper, 
Lostof, and Kaplan mention that as of 2006, they were aware of eleven deaths that 
occurred within seventy-two hours of the administration of ibogaine. “Deaths were most 
commonly attributed to a cardiac cause in association with significant risk factors such as 
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a prior myocardial infarction, cardiomyopathy or valvular disease, or to pulmonary 
embolus. Other deaths were regarded as mixed drug overdoses.”81  In one of the cases, 
the individual who died consumed more than twice the maximum dose of ibogaine. This 
reminds us again of the dangers of underground clinics with no legal or professional 
medical supervision, yet another harmful consequence of prohibition. People with 
preexisting heart conditions should never be given ibogaine, and if it were legal, many of 
these deaths could have been easily avoided. Alper et al., argue that these fatalities 
underscore “the need for the security procedures and medical supervision available in a 
conventional medical setting and for completion of the FDA dose escalation studies to 
allow systematic collection of pharmacokinetic and safety data.”82  Moreover, any risks 
of ibogaine must be weighed against the dangers of MMT, yet NIDA’s concerns 
somehow disappear when over 4,000 people die from methadone in one year.  
One additional concern is the potential neurotoxicity of ibogaine at high doses. 
Rats treated with 100 milligrams of ibogaine per kilogram of body weight suffered 
cerebellar damage.83  However, the dose necessary to reduce self-administration of 
morphine or cocaine in rats was a mere 40 mg/kg, and there was no evidence of toxicity 
at these lower doses. Even water is lethal at high doses, so the fact that ibogaine is 
dangerous in excessive amounts in no way indicative of its effects at proper doses. 
Moreover, this neurotoxicity has only been observed in rats, but not in mice, primates, or 
humans.84 
The powerful hallucinogenic properties of ibogaine make many people uneasy 
about its potential to treat addictions to other drugs, but it is important to recognize that 
the “trip” of the drug may not be wholly unrelated to ibogaine’s anti-addictive properties. 
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Alper explains that unlike traditionally abused hallucinogens such as LSD, the experience 
of ibogaine is more like a dream than a hallucination. Thus he prefers the term “oneiric” 
to “hallucinogenic” in describing the subjective experience of ibogaine. According to The 
Iboga Foundation, a Dutch non-profit organization, “Many users of ibogaine report 
experiencing visual phenomena during the waking dream state, such as instructive 
replays of life events that led to their addiction, while others report therapeutic shamanic 
visions that help them conquer the fears and negative emotions that might drive their 
addiction.”85  Many researchers believe that these introspective, self-reflective aspects of 
the ibogaine experience are integral to making the user reevaluate his drug use. Alper et 
al. posit, “the material recalled in the psychoactive state might have potential 
psychotherapeutic significance.”86  In contrast, some ibogaine experts believe the “trip” is 
irrelevant to ibogaine’s healing power. 
Stanley Glick, a leading ibogaine researcher at Albany Medical College, argues, 
“The hallucinations are just an unfortunate side effect. Part of the problem is that when 
you go through this thing, it's so profound you've got to believe it's doing something. In 
part, it's an attempt by the person who's undergoing it to make sense of the whole 
thing.”87   Dmitri Mugianis disagrees. Mugianis, a former heroin addict who got clean 
after Howard Lotsof gave him ibogaine and has been helping other addicts overcome 
addiction with ibogaine ever since, is the subject of the documentary I’m Dangerous with 
Love. He contends, “With methadone, they just removed euphoria from opiates. This is 
the same process they're doing now—removing psychedelic and visionary experience. 
Ibogaine works. What are they trying to improve or fix? It's not broken, and they're 
spending a great amount of time and money to fix it.”88  The spiritual aspect also 
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increases patient autonomy by making them feel like they want to quit rather than feeling 
forced. 
 It is significant that ibogaine treatment is a onetime event rather than a maintained 
treatment. As discussed, a severe problem with MMT is low rates of retention. With a 
onetime treatment, the problem of retention completely disappears. Moreover, the 
potential for an immediate cure is extremely cost effective. Farrell et al. explain, 
“Treatments such as methadone maintenance are costly, particularly because of the 
duration of treatment.”89  In contrast, “[i]bogaine can presently be purchased at a 
wholesale price of approximately 200 US dollars per treatment, and that price  could drop 
considerably if significant demand were to stimulate increased production.”90  A 
downside of onetime treatment is that it means that following up with patients may be 
challenging at times. 
It should also be noted that, as mentioned, ibogaine has been shown to be an 
effective anti-addictive agent for more than just heroin. It also has the potential to cure 
addictions to alcohol, cocaine, morphine, methadone, and nicotine. This only adds to the 
benefits that would come from legalizing ibogaine treatment. At the very least, ibogaine 
research deserves significantly more funding. Perhaps ibogaine still needs to prove more 
effective and completely safe, but the results thus far certainly justify further research. 
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CHAPTER VI 
NEEDLE EXCHANGE PROGRAMS 
 
 
One of the problems of addiction that is specific to heroin use is the risk of 
contracting HIV or hepatitis C as the result of sharing needles. This is due to the fact that 
the majority of drugs are smoked or insufflated, while heroin’s primary method of 
administration is through intravenous injection.91  This has led to the concept of needle 
exchange programs, where addicts can obtain free needles with no threat of legal 
retaliation. Intravenous drug users are often required to exchange a contaminated needle 
for a clean one in an effort to ensure that contaminated needles stay off the streets, hence 
the name needle exchange program. 
Elisabeth Pisani, a public health expert who has studied HIV for 15 years, 
expounds on the benefits of needle exchange programs in a 2010 TED talk titled Sex, 
Drugs, and HIV: Let’s Get Rational. She introduces the idea that despite the risks of 
sharing needles, addicts are forced to make that dangerous decision by circumstances 
beyond their control. “People do get HIV because they do stupid things,” she says, “but 
most of them are doing stupid things for perfectly rational reasons.”92 
Pisani interviewed nearly 600 addicts in Indonesia and asked them how people get 
HIV. Almost 100 percent of them fully understood the risks of sharing needles. They also 
knew where to get cheap clean needles, yet a maximum of one in four were actually 
carrying clean needles on them, and sadly, only one in ten used clean needles when they 
had injected in the past week.93  So what explains this apparent discrepancy between 
knowledge and behavior? 
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In Indonesia, it is illegal to carry a syringe without a doctor’s prescription. Heroin 
addicts know this, and don’t want to risk getting arrested for something that isn’t 
absolutely necessary in order to get high. Pisani spoke with addicts on the street who told 
her, “You don’t want to share a needle any more than you want to share a toothbrush, 
even with someone you’re sleeping with. There’s just a kind of ick factor there…we 
share needles because we don’t want to go to jail.”94  Laws regulating the possession of 
syringes in the United States vary from state to state, but if an injecting drug user is found 
with a needle that has been contaminated by drugs, that is sufficient for arrest in twenty-
nine states.95  Burris et al. found that this is also sufficient to deter users from carrying 
clean needles, and thus encourages risky needle sharing.96 
Pisani relates the story of Frankie, a heroin addict she interviewed who had been 
in prison. One day, someone smuggled in some heroin for another inmate’s birthday, and 
kindly decided to share it with his friends. A group of more than twenty inmates lined up, 
and one person went down the line injecting each person one by one. With no access to 
anything to use to sterilize the needle, the injector simply wiped the bloody needle on his 
shirt after each injection. Frankie stood there thinking about how he was twenty-second 
in line. He recalled, “‘A small part of my brain is thinking, That is so gross and really 
dangerous. But most of my brain is thinking, please let there be some smack left by the 
time it gets to me.’”97  Although Frankie recognized the stupidity of his decision to use 
such a disgusting needle, Pisani explains that it was nonetheless a rational choice for 
someone in Frankie’s situation. “Frankie at that time was a heroin addict and he was in 
jail, so his choice was either to accept that dirty needle or not to get high. And if there’s 
one place you really want to get high, it’s when you’re in jail.”98  In Frankie’s mind, he 
  
was choosing the lesser of two evils
Many addicts face a similar conundrum on a
really bad idea to expose themselves to HIV, they think it’s a much worse idea to spend 
the next year in jail, where they’ll probably end up in Frankie’s situation and expose 
themselves to HIV anyway.”
The first needle exchange program was introduced in England by Margaret 
Thatcher, and Australia and the Netherlands soon followed suit
those countries surpassed a rate of 3.5 percent of HIV prevalence among injecting drug 
users in their highest year since
peaked at 45, 50, and 55 percent, respectively, as the graph below shows.
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Yet while needle exchange programs are growing in the United States, they are 
still relatively rare. This is largely because Congress banned the use of federal funds for 
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needle exchange programs in 1989. President George W. Bush’s drug czar, John Walters, 
argued that needle exchange programs do not “pass any serious test of rationality. It's like 
the surgeon general deciding that handing out lighters is a good way to help people to 
stop smoking. It's at least that absurd, and the consequences are even greater given the 
risks involved in IV drug use.”102  But Walters clearly misses the point—no one endorses 
needle exchange programs as a way to decrease drug use; people support them because 
they prevent thousands of people from contracting deadly and communicable diseases, 
harming themselves and putting the rest of society at risk. Clark and Fadus condemn the 
ban, noting, “This ban was introduced by Congress in accordance with the drug war 
ideology, a narrow and elusive plan to completely eradicate drug use in the United States. 
Although there are a significant number of government reports supporting needle 
exchange programs, including support from the CDC, American Medical Association, the 
National Institutes of Health, it appears as if public health and the lives of others have 
become a secondary concern to strong federal policy on eradicating drug use.”103 
Indeed, the evidence is undeniable that needle exchange programs prevent the 
spread of HIV and hepatitis C. The chart below compares numerous studies on the 
effectiveness of needle programs at reducing the transmission of HIV. The studies on the 
left have demonstrated the effectiveness of needle exchange programs. An exhaustive list 
of the studies that have shown that needle programs are not effective is presented on the 
right—they simply do not exist, because needle exchange programs are universally 
effective at preventing the spread of diseases acquired through needle sharing. 
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Critics maintain that these programs promote drug use, but there is not a shred of 
evidence to support these claims. In fact, studies have demonstrated that many needle 
exchange programs encourage addicts to seek treatment, thereby decreasing drug use.105  
According to the American Psychiatric Association’s Commission on AIDS, “After 
extensive review of the current available research, the panel members further concluded 
that needle exchange programs do not increase the amount of drug use by those using 
such programs, and do not increase overall community levels of new or continued 
injection or noninjection drug use.”106  Fortunately, President Obama has heeded these 
results. He recently repealed the ban on using federal funds for needle exchange 
programs and began funding them. 
 No matter how much we learn about addiction, people persist in blaming addicts 
for their behavior. In The Fallacies of No-Fault Addiction, Sally L. Satel argues, addicts 
“are the instigators of their own addiction, just as they can be the agents of their own 
Do sterile needle programmes reduce HIV 
transmission?  Reviews of the evidence
Studies showing needle 
progrmmes ARE effective
The National Commission on AIDS 
The General Accounting Office
The Centers for Disease Control and Prevention
The Office of Technology Assessment of the US Congress
The National Institutes of Health
The American Medical Association
The United States Surgeon General
The Institute of Medicine
The National Academy of Sciences
Studies showing needle 
programmes ARE NOT effective
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recovery.”107  While we should not absolve addicts of all personal responsibility for their 
decisions, it is dangerous to downplay heroin’s powerful addictive properties and 
perpetuate dispassionate attitudes towards addicts. Pisani describes what she coins “the 
compassion conundrum,” explaining that people are hesitant “to be giving out needles to 
junkies, but once they’ve gone from being transgressive people whose behaviors we 
don’t want to condone to being AIDS victims, we come over all compassionate and buy 
them incredibly expensive drugs for the rest of their lives. It doesn’t make any sense from 
a public health point of view.”108  Not only does this make little sense from a public 
health standpoint, it also makes no sense from an economic standpoint. As Pisani 
mentions, anti-retroviral medication to treat AIDS patients is extremely expensive, and 
all of society incurs large costs when one person gets HIV. It is hundreds of times more 
cost-effective to provide addicts who will inject anyway with cheap clean needles and 
prevent these cases of HIV in the first place.  
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CHAPTER VII 
 
THE BENEFITS OF EDUCATION 
 
 
Despite all of the efforts of the government and law enforcement, there are still 
millions of illicit drugs users in the United States. Clearly, the lure of drugs is enticing 
enough to attract people to illicit substances in spite of their health risks and illegality. 
When citizens make the decision to use substances in violation of the law, they 
knowingly relinquish certain rights. For example, they relinquish the right to travel, if 
they are convicted of a crime and incarcerated. However, there are other rights that no 
American can ever relinquish—it would be draconian and unconstitutional to deny 
inmates access to proper water, food, or health care. Education is an equally fundamental 
right, especially regarding one’s personal safety. Nevertheless, the same anti-drug 
crusaders who decry needle exchange programs often oppose any education about how to 
use drugs safely on the grounds that it encourages use. This is akin to abstinence-only 
sexual education, and it simply does not work.  
There are a few basic pieces of information that could save hundreds of lives if all 
heroin users were privy to them. Some of these are obvious, and likely widely known in 
drug communities. For instance, as Elizabeth Pisani demonstrated, most injecting drug 
users understand the risks of acquiring diseases such as HIV or hepatitis C that come 
from sharing needles, even if that knowledge fails to stop the majority of heroin users 
from avoiding this dangerous practice. But some other information is much less well 
known. 
For example, Shephard Siegel reports in Addiction Research and Theory that 
injecting heroin in a new place is significantly more likely to be fatal.109  This is 
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extremely counterintuitive, and unless addicts are actively taught this information, they 
have little hope of knowing this fact that could very well save their lives. Siegel explains 
that injecting heroin in a new place is more dangerous as a result of a complex process of 
Pavlovian conditioning. While most fatalities from heroin are classified as overdoses, in 
fact most people who die from heroin die of respiratory depression, not an overdose in 
the usually understood pharmacological sense of the term. Siegel introduces the concept 
of the “situational specificity of tolerance” to convey the idea that tolerance to a drug is 
variable, not static, dependent on time, place, route of administration, and any other cues 
that subconsciously prepare a user’s body for the drug. If an addict typically injects at 
home, then when he is home his body will preemptively try to fight the foreign poison 
before he injects. However, the body is not primed for this response in new locations, and 
thus, a dose that may be safe in the usual injecting location is significantly more likely to 
be lethal in a new place. Despite the fact that it would be obviously unethical, and is 
therefore impossible, to test the concept of situational specificity of tolerance on humans, 
there is a plethora of evidence to support this claim. 
Siegel references a study conducted on rats in which two groups were injected 
with 15 mg/kg of heroin. Both groups had previously been given heroin to establish a 
tolerance, but in this experiment, one group was given the drug in a novel location, while 
the other was given heroin in the same location as previous injections. Thirty-two percent 
of the rats drugged in the same location as before died, while an astounding twice that 
percentage (64 percent) of the rats that were injected with heroin in a novel location 
died.110 
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Gutierrez-Cebollada et al. observed this phenomenon in human patients. They 
interviewed 76 heroin users admitted consecutively to a hospital in Spain. Fifty-four of 
the patients had suffered an overdose, while the other twenty-two were admitted for other 
health problems but had nonetheless injected heroin within an hour prior to their trip to 
the hospital. Every single one of the twenty-two users who did not overdose had injected 
in a typical location. In contrast, 52 percent of those who suffered an overdose had 
injected in “an unusual setting.”111 
Darke and Zador also discuss the phenomenon of situationally specific tolerance. 
They explain that if tolerance were static, one would expect heroin users who die to have 
higher levels of morphine (heroin’s metabolite) in their blood than users who survive. 
However, they found that this was not the case, further cementing the idea that most 
“overdoses” are not technically overdoses in the pharmacological sense of the term; 
rather they are the result of the user injecting more heroin than his specific situational 
tolerance could endure at one particular time or place.112  Siegel concludes his report by 
critiquing the fact that this increased danger of injecting in unfamiliar settings is not 
publicized, noting, “Based on the available evidence, such behavior should be considered 
dangerous.”113 
Darke and Zador also report on the high prevalence of polydrug use among 
supposed heroin overdoses. They contend that in many deaths attributed to heroin 
overdose, other drugs are likely causal factors. The average morphine level in the blood 
in overdoses without alcohol is nearly twice the average level for fatalities resulting from 
a combination of heroin and alcohol, suggesting that alcohol significantly increases the 
likelihood of overdose given a fixed amount of heroin. Recognizing the importance of 
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education, the authors argue, “An important finding from the literature is the major 
contributory role of other CNS [Central Nervous System] depressants in ‘heroin’ 
overdoses. The reduction of concomitant use of alcohol and/or benzodiazepines with 
heroin could be expected to reduce the frequency of heroin-related deaths. Interventions 
targeted towards reduction of concurrent depressant drug use seem warranted.”114  
Education is a virtue in and of itself—but when it can save lives with little effort, it is a 
necessity. 
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CHAPTER VIII 
 
DECRIMINALIZATION, LEGALIZATION, AND  
MANDATORY REHABILITATION 
 
 
Imprisonment denies citizens many of the rights to which Americans are 
otherwise entitled, and thus it requires significant justification. There are four classic 
justifications for a government to incarcerate its citizens: deterrence, incapacitation, 
retribution, and rehabilitation. Let us now examine how each of these justifications 
applies in the case of the incarceration of heroin addicts. Retribution is reserved for 
crimes with victims, and so it is an invalid justification for incarcerating drug addicts. 
However, the other three justifications are all applicable. 
The only way to properly measure the deterrent effect of criminalizing a particular 
behavior is through a comparison of the prevalence of said crime before and after the 
behavior is either newly criminalized or newly legalized. Unfortunately, a good 
opportunity for this analysis has yet to present itself, so any conclusions about the 
deterrent effect of criminalizing heroin use are purely speculative. 
The ideas of incapacitation and rehabilitation are interrelated. Presumably, the 
primary goal of incarceration, on an individual level, is rehabilitation (as compared with 
goals such as deterrence on the societal level). Thus, incapacitation is a valid justification 
for incarceration only until the individual is properly rehabilitated. It seems, then, that 
rehabilitation is the only legitimate governmental goal of imprisoning an individual for 
heroin use. If this is the case, then must we imprison them at all?  Is that really the best 
way to rehabilitate a heroin addict? 
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It seems clear that the answer to these questions is a resounding no. As previously 
mentioned, the psychiatric community now recognizes addiction as a disease, but the law 
has not caught up to this new understanding. Once we acknowledge that incarceration is 
not a form of medical rehabilitation, we are left with three primary policy options to 
attempt to control drug use and the crime often associated with the world of illicit drugs. 
The first method is decriminalization. Decriminalization of heroin could manifest 
in many forms, but the basic idea would be that possession of small amounts of heroin 
would no longer constitute a criminal offense, and thus would not be subject to criminal 
penalties, i.e., incarceration. However, decriminalization would still allow for civil 
penalties, i.e., fines, for the possession of heroin, and it need not change the laws and 
penalties for smuggling, selling, distributing to a minor, or driving under the influence.  
There is precedent for drug decriminalization in the United States with marijuana. 
Alaska was the first state to decriminalize marijuana in 1973. Twelve other states have 
followed since: California, Colorado, Maine, Massachusetts, Minnesota, Mississippi, 
Nebraska, Nevada, New York, North Carolina, Ohio and Oregon. Fortunately, this allows 
for a comparison between prevalence of marijuana use pre-decriminalization and post-
decriminalization. A simple comparison is not quite adequate, though, because there are 
constantly changing trends of drug use. However, we can analyze whether or not the 
decriminalization of marijuana has had an effect on use in these thirteen states by 
comparing the trends of marijuana use in these states to the trends in the same years in 
the other thirty-seven states. 
According to the National Organization for the Reform of Marijuana Laws 
(NORML), “Findings from dozens of government-commissioned and academic studies 
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published over the past 25 years overwhelmingly affirm that liberalizing marijuana 
penalties does not lead to an increase in marijuana consumption or affect adolescent 
attitudes toward drug use.”115  In The Impact of Marijuana Decriminalization: An 
Update, Eric W. Single reports on a few such studies. In one, “Data collected at four 
points in time in Ann Arbor and the control communities (which underwent no changes 
in marijuana penalties) indicated that marijuana use was not affected by the changes in 
law.”116  The second study found an increase in use after decriminalization, “However, 
the increase in marijuana use was even greater in other states and the largest 
proportionate increase occurred in those states with the most severe penalties.”117  Single 
coauthored another article eleven years later with similar conclusions, asserting, “The 
reduction of maximum penalties for cannabis possession to exclude the possibility of 
receiving a jail sentence has had no discernible impact on rates of cannabis use or 
problems associated with cannabis use. This was true in all of the jurisdictions in 
Australia and the United States that enacted decriminalisation measures.”118  Given 
classic economic models, it may seem counterintuitive that reducing the penalty for 
use—thereby increasing incentives to smoke marijuana—did not lead to a subsequent 
increase in use. However, Single et al. explain, “simple lack of interest or fear of adverse 
health consequences are the most commonly given reasons for abstention from cannabis 
use.”119  Fear of legal consequences is rarely the reason that people abstain from smoking 
marijuana. 
 It seems clear that decriminalization of marijuana does not in fact promote use, 
but how analogous would the decriminalization of heroin be?  What are the relevant 
differences and similarities between heroin and marijuana?  The most striking difference 
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is that heroin is intensely addictive, while marijuana is not addictive at all. This has a few 
important implications: since no one in the United States is currently physically addicted 
to marijuana, it stands to reason that few people feel compelled to use marijuana in spite 
of the law. On the contrary, heroin addicts feel they have no choice but to find their next 
heroin fix regardless of what the law says. Thus, one might expect that even if 
decriminalization increased marijuana consumption, those interested in using heroin 
would be even less likely to be deterred by heroin’s criminal status. 
 On the other hand, heroin is widely viewed—rightly so—as a much more serious 
drug than marijuana. If it were decriminalized, it could send the message to society that it 
is not in fact severely addictive or dangerous. Moreover, if this were the case, and 
decriminalization increased the number of heroin initiates, this would create lots of new 
heroin addicts because of heroin’s abnormally high capture rate. 
 Legalization is essentially a more extreme version of decriminalization. Full-scale 
legalization would eliminate any penalties for personal heroin use. However, just as 
alcohol is legal but regulated, the government would most certainly regulate heroin. 
Perhaps there would be a license to sell heroin, similar to the current system with alcohol, 
or the government itself might take over the heroin distribution business. There would 
undoubtedly still be a minimum age, likely eighteen or twenty-one, before an individual 
could legally use heroin. As with decriminalization, there would not necessarily be any 
change in the laws regulating selling, smuggling, distributing to a minor, or driving under 
the influence. 
One of the biggest benefits of legalization that distinguishes it from 
decriminalization would be the tax revenue gained from the sale of heroin. As with 
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cigarettes and alcohol, the government could impose high “sin taxes” on heroin to both 
discourage its use and raise revenue. While decriminalization would raise some revenue 
from the fines, it would pale in comparison to the potential tax revenue from legalization, 
which could be used to fund an aggressive education campaign discouraging drug abuse. 
Moreover, the government could carefully regulate and maintain the purity level of 
heroin, decreasing the chances of overdoses. If the government were to take control of the 
heroin industry, it could also ensure that anyone buying heroin were fully informed of the 
health risks before allowing them to purchase it. Legalization entails the same risks of 
increased use as decriminalization, though perhaps they are augmented with full-scale 
legalization. 
One danger of legalization, particularly if the heroin industry were privately run, 
would be the advertising campaigns of those who stood to benefit from addicting people 
to heroin. We have already seen the devastating consequences of the tobacco industry’s 
advertisement campaigns, specifically those targeted at adolescents. Any system that 
creates incentives for companies to promote heroin use sets a dangerous precedent. 
One other possible heroin policy is the idea of mandatory rehabilitation. As 
discussed earlier in this chapter, the primary goal of incarcerating heroin addicts is to 
rehabilitate them. So why not do that explicitly?  Instead of sending addicts to prison, a 
system of mandatory rehabilitation would send them to a government-run rehabilitation 
facility. (The facilities would not necessarily need to be run by the government, but 
giving private companies—whose ultimate goal is to make a profit—control over people 
who are involuntarily confined to a facility presents myriad opportunities for abuse. This 
is a similar argument to the arguments against prison privatization, but that is a topic for 
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another time.)  Mandatory rehabilitation is similar to drug court treatment programs, 
except that the system I propose would be in-patient, so the addicts could be carefully 
monitored, and would not have any access to drugs. This would ensure a retention rate of 
100 percent. 
Perhaps the facility would use MMT, ibogaine, or simple detoxification. In order 
to ensure that no addicts are worse off as a result of this policy, they should be given the 
option to serve the prison sentence they would have served under the previous system if 
they so choose. They should also be given the opportunity to choose whichever treatment 
method they prefer, as citizens are normally entitled to make autonomous decisions about 
their own medical treatment. 
In Human Rights Quarterly, Saul Takahashi cautions, “the right to the highest 
attainable standard of health includes the right to be free from involuntary medical 
treatment of any kind.”120  However, at the same time he acknowledges that some level of 
involuntariness might be necessary in order to aid the addict in overcoming his or her 
addiction. Moreover, “[t]he reality of drug addiction is that it destroys—or at least 
suspends—the free will of the addict.”121  Committing someone who is resistant to 
treatment may be in accord with their second order desires even if it does not comport 
with their first order desires. In other words, an addict may not want to go to treatment, 
but at the same time they may wish that they were not addicted to heroin, and that they 
wanted to seek treatment. 
Anglin, Prendergast, and Farabee note that some researchers claim, “little benefit 
can be derived when a drug user is forced into treatment by the criminal justice 
system…treatment can be effective only if the person is truly motivated to change.”122  
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They reviewed eleven studies that analyzed the different outcomes of voluntary and 
involuntary treatment programs. The studies used inconsistent terminology and defined 
voluntary on different criteria, thus meta-analysis was challenging. Some studies found a 
positive correlation between level of coercion and treatment outcomes, some were 
neutral, and others were negative. Nonetheless, the evidence was strong enough for the 
authors to conclude, “In general, our review of 11 empirical studies of compulsory 
substance abuse treatment supports the use of the criminal justice system as an effective 
source of treatment referral, as well as a means for enhancing retention and 
compliance.”123 Although voluntary treatment should always be preferable to coerced 
treatment, coerced treatment seems universally preferable to coerced incarceration. 
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CHAPTER IX 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
 
 We have seen the plethora of problems that result from the current heroin policy. 
Thousands of non-violent citizens are in prison, and still, heroin kills thousands of people 
every year. While hundreds of thousands of Americans are addicted to heroin, few are 
receiving adequate medical treatment for their condition. Many injecting drug users are 
also infected with hepatitis or HIV. 
 These problems affect all Americans, not just addicts. Incarceration and 
prosecution cost millions of taxpayer dollars every year. Emergency room costs and lost 
workdays are a drag on the economy. And when injecting drug users acquire HIV, they 
put others, especially their loved ones, at risk for contracting the disease, too. The crime 
that frequently results from addiction also clearly harms society as a whole. 
 The black market created by the criminalization of heroin is the cause of many of 
these social ills. But legalization of such a dangerous and addictive drug is an 
unsatisfactory alternative until we can be more certain of what the impact of full-scale 
legalization would be. Furthermore, even in California, one of the more liberal states in 
the country, the attempt to legalize marijuana through Proposition 19 narrowly failed. If 
California is not ready for marijuana legalization, the country is far from considering the 
idea of legalizing heroin. 
Decriminalization would cease to make all addicts inherently criminal, and would 
save millions on costs of prosecution and incarceration. It has the added benefit of not 
appearing to some as a tacit government endorsement of illicit drug use. Moreover, 
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evidence from the experiments with marijuana decriminalization suggests that it does not 
increase use, although the analogy to heroin may be imperfect. 
A system of mandatory treatment has the most potential to reduce harm, treat 
addicts, and help them comfortably reintegrate into society. Decreasing the rates of 
recidivism and relapse benefit all of society. A downside of mandatory treatment is that it 
would not raise the revenue that a system of legalization, regulation, and taxation would 
raise, and rehabilitation programs would of course cost a significant amount of money. 
However, it is doubtful that the expense would exceed the current costs of incarceration, 
especially since the average stay in rehab would likely be far shorter than the average 
prison sentence for heroin use. The system of drug courts that already exists is a model 
for what mandatory rehabilitation would look like. 
 Rehabilitation centers could offer multiple forms of treatment for addiction. 
While methadone has been shown to be effective at reducing crime, drug use, and the 
transmission of HIV and hepatitis C, it also has many negative aspects. It simply 
substitutes one addiction for another, and the withdrawal from methadone is as 
excruciating as heroin withdrawal. Methadone use can also be deadly, especially when 
mixed with other drugs. Rates of retention in methadone maintenance programs are 
discouragingly low, although this would obviously not be in the case in a mandatory 
treatment setting. 
 Ibogaine is a promising alternative to methadone. Although the research on 
ibogaine is nowhere near as extensive as that on methadone, experiments by Alper et al. 
and Mash et al. demonstrated that ibogaine eliminates withdrawal symptoms and reduces 
craving, which is a significant step in helping people overcome their addictions. Ibogaine 
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has also been shown to decrease depression, which improves the prospects for addicts 
who self-medicate with drugs to combat this illness. Ibogaine should be rescheduled so 
that it can be used to treat addiction. This would also eliminate the black market for 
ibogaine clinics and move treatment into the proper medical setting. 
 Needle exchange programs have proved effective time after time in reducing the 
transmission of HIV and hepatitis C. Although critics decry the supposed endorsement of 
illicit drug use, no studies indicate that these programs encourage drug use. Now that 
federal funding can finally be used to fund needle exchange programs, Congress should 
fund programs in every major city in an effort to combat the HIV epidemic. 
 The government should also run aggressive advertising campaigns to educate 
addicts about some of the lesser-known dangers of heroin. Specifically, addicts should be 
taught the dangers of combining heroin with alcohol or benzodiazepines. They should 
also be educated about the concept of situationally specific tolerance, which could save 
hundreds of lives. The networks already exist to disseminate this information at MMT 
clinics or needle exchange programs. Perhaps in ten years or so, the country will be ready 
for more radical systemic change in our drug policy. Until then, instituting needle 
programs, expanding the drug court system, and educating addicts could greatly alleviate 
the serious social and economic problems the United States faces as a result of 
widespread heroin abuse. 
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